Clinical Trials Logo

Cirrhosis clinical trials

View clinical trials related to Cirrhosis.

Filter by:

NCT ID: NCT05737030 Recruiting - Cirrhosis Clinical Trials

Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome

LOLAbiome
Start date: February 6, 2023
Phase: Phase 4
Study type: Interventional

Study to test the effect of the drug "L-ornithine.L-aspertate" (LOLA) on microorganisms in the digestive tract in patients with liver cirrhosis (damage of the liver due to liver disease)

NCT ID: NCT05726032 Recruiting - Cirrhosis Clinical Trials

Empagliflozin in Patients With Cirrhosis and Ascites

EMPA Liver
Start date: September 11, 2023
Phase: Phase 2
Study type: Interventional

A proof-of-concept placebo-controlled trial to explore the acute and 14-day effects of empagliflozin on natriuresis and total body water in patients with cirrhosis and ascites. We will additionally investigate its effect on neurohumoral activation, and renal hemodynamics.

NCT ID: NCT05724485 Completed - Quality of Life Clinical Trials

Effect of Branched-chain Amino Acids (BCAA) to Muscle Cramps in Patients With Cirrhosis

Start date: April 1, 2023
Phase: Phase 4
Study type: Interventional

The goal of this randomized controlled trial is to compare the efficacy and safety of branched-chain amino acids (BCAA) versus placebo for treating muscle cramps in cirrhotic patients. The main questions it aims to answer are: - Compared the effect of BCAA versus placebo on muscle cramp frequency in cirrhotic patients - Compared the effect of BCAA versus placebo on muscle cramp duration and severity in cirrhotic patients - Compared the effect of BCAA versus placebo on quality of life in cirrhotic patients with muscle cramps Participants with cirrhosis who have experienced muscle cramps at least once per week will be randomized to receive either a placebo or 12.45 grams of BCAA orally per day for 12 weeks.

NCT ID: NCT05689268 Completed - Cirrhosis Clinical Trials

EUS-PPG vs HVPG in Portal Hypertension

GRAPE
Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the correlation of the calculated portal pressure gradient (PPG) obtained by direct portal and hepatic pressure measurements with a conventional 22 G needle guided by EUS and indirect portal vein pressure measurements using the interventional radiology based hepatic venous pressure gradient (HVPG) procedure.

NCT ID: NCT05635266 Recruiting - Stroke Clinical Trials

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Start date: October 26, 2021
Phase:
Study type: Observational

To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.

NCT ID: NCT05548452 Recruiting - Clinical trials for Alcohol Use Disorder

Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease

IMPACT
Start date: November 21, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this research study is to test the safety, tolerability, and effectiveness of the capsules that contain bacteria from healthy individuals when used to treat alcohol craving and drinking.

NCT ID: NCT05545670 Completed - Cirrhosis Clinical Trials

Allopurinol to Prevent Cirrhosis Related Morbidities

Start date: June 15, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The study aims to compare the potential benefit of allopurinol in reducing the risk of developing cirrhosis-related complications, delaying the onset of hepatocellular carcinoma, and improving survival. Furthermore, the study aims to evaluate their impact on parents' related quality of life

NCT ID: NCT05541601 Recruiting - Clinical trials for Hepatocellular Carcinoma

Prospective Cohort for Early Detection of Liver Cancer

Pearl
Start date: February 23, 2022
Phase:
Study type: Observational

This study aims to recruit 3000 people with liver cirrhosis into a Prospective cohort for early detection of Liver cancer - the Pearl cohort. The study team believe that using a combination of novel tests may improve the detection of early Hepatocellular Carcinoma (HCC).

NCT ID: NCT05538546 Not yet recruiting - Cirrhosis Clinical Trials

Baveno VI Criteria in Dynamic Monitoring of High-risk Varices in Compensated Cirrhotic Patients

CHESS2204
Start date: September 2022
Phase:
Study type: Observational

Patients meet Baveno VI criteria (with a liver stiffness <20kPa and with a platelet count >150,000 are considered to have very low risk of having varices requiring treatment, but whether these patients can be followed up by repetition of this criteria lacks sufficient evidence. This study aimed to assess the value of Baveno VI criteria for following up and monitoring of varices needing treatment in patients with compensated cirrhosis.

NCT ID: NCT05511766 Recruiting - Cirrhosis Clinical Trials

Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis

Start date: November 15, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The study aims to compare the potential benefit of allopurinol versus atorvastatin in reducing the risk of developing cirrhosis-related complications, delaying the onset of hepatocellular carcinoma, and improving survival. Furthermore, the study aims to evaluate their impact on parents' related quality of life.